文献速递妇科

辅助治疗在中危宫颈癌患者中的作用——SCCAN研究亚组分析

Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study.
PubMed 文献 · Gynecol Oncol · 2023-01-25

基于SCCAN国际多中心回顾性研究,分析2007至2016年间接受根治性手术的692例中危早期宫颈癌患者,其中274例(39.6%)未接受辅助治疗,418例(60.4%)接受放疗或放化疗。两组5年无病生存率(83.2% vs 80.3%)和总生存率(88.7% vs 89.0%)均无显著差异,辅助放化疗未显示生存获益。

要点

  • 中危早期宫颈癌根治术后辅助放化疗未显示生存获益
  • 5年无病生存率AT-组83.2% vs AT+组80.3%,无显著差异
  • 5年总生存率AT-组88.7% vs AT+组89.0%,无显著差异

核心结论

  • 在中危早期宫颈癌患者中,单纯根治性手术获得的无病生存率和总生存率与根治性手术联合辅助放化疗相当。

研究设计与样本

  • 国际多中心回顾性研究SCCAN的亚组分析,纳入2007至2016年间接受初次根治性手术的中危宫颈癌患者692例,其中未接受辅助治疗274例(39.6%),接受放疗或放化疗418例(60.4%)。

主要发现

  • 未辅助治疗组与辅助治疗组的5年无病生存率分别为83.2%和80.3%(P=0.365),无显著差异。
  • 未辅助治疗组与辅助治疗组的5年总生存率分别为88.7%和89.0%(P=0.281),无显著差异。
  • 经病例对照倾向评分匹配调整混杂因素后,辅助放化疗未与生存获益相关。
  • 在肿瘤大小≥4 cm和<4 cm的亚组分析中,辅助放化疗均未与生存获益相关。
  • 单因素分析中,辅助放化疗在任何亚组中均未被确定为预后因素(全队列:无病生存P=0.365;总生存P=0.282)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The "intermediate-risk" (IR) group of early-stage cervical cancer patients is characterized by negative pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size ≥2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuvant treatment in these patients remains controversial. We investigated whether adjuvant (chemo)radiation is associated with a survival benefit after radical surgery in patients with IR cervical cancer. METHODS: We analyzed data from patients with IR cervical cancer (tumor size 2-4 cm plus LVSI OR tumor size >4 cm; N0; no parametrial invasion; clear surgical margins) who underwent primary curative-intent surgery between 2007 and 2016 and were retrospectively registered in the international multicenter Surveillance in Cervical CANcer (SCCAN) study. RESULTS: Of 692 analyzed patients, 274 (39.6%) received no adjuvant treatment (AT-) and 418 (60.4%) received radiotherapy or chemoradiotherapy (AT+). The 5-year disease-free survival (83.2% and 80.3%; PDFS = 0.365) and overall survival (88.7% and 89.0%; POS = 0.281) were not significantly different between the AT- and AT+ groups, respectively. Adjuvant (chemo)radiotherapy was not associated with a survival benefit after adjusting for confounding factors by case-control propensity score matching or in subgroup analyses of patients with tumor size ≥4 cm and <4 cm. In univariable analysis, adjuvant (chemo)radiotherapy was not identified as a prognostic factor in any of the subgroups (full cohort: PDFS = 0.365; POS = 0.282). CONCLUSION: Among patients with IR early-stage cervical cancer, radical surgery alone achieved equal disease-free and overall survival rates to those achieved by combining radical surgery with adjuvant (chemo)radiotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cibula D, Akilli H, Jarkovsky J, et al. Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study. Gynecol Oncol. 2023. PMID: 36706646. doi:10.1016/j.ygyno.2023.01.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。